Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan.
Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya-shi, Aichi, Japan.
Hum Psychopharmacol. 2024 May;39(3):e2890. doi: 10.1002/hup.2890. Epub 2024 Jan 5.
In psychiatry, polypharmacy or high psychotropic drug doses increase adverse drug event (ADE) prevalence. However, the full relationship between polypharmacy and ADEs is unclear, and few studies have evaluated dose equivalents for psychotropic drugs for ADEs. Thus, we conducted a retrospective analysis to clarify the effects of polypharmacy and chlorpromazine (CP)-, diazepam (DAP)-, and imipramine- equivalent doses on all ADEs in inpatients.
Psychiatric inpatients in a Japanese hospital from April 1, 2016 to March 31, 2018, were enrolled. ADE severity and causality were assessed. Multiple logistic regression analyses were performed to evaluate ADE risk factors.
Among 462 patients analyzed, out of 471 patients enrolled, 145 (31.4%) experienced ADEs. The causality assessment determined that "possible" was 96.5%. The most common ADEs were nervous system disorders (35%). Multiple logistic regression analyses indicated an increase in ADE prevalence with the number of drugs used (≥5; p = 0.026); CP-equivalent dose (p = 0.048); and endocrine, nutritional, and metabolic disorders (p = 0.045). DAP-equivalent dose; infectious and parasitic diseases; and injury, poisoning, and consequences of other external causes decreased ADE prevalence (p = 0.047, 0.022, and 0.021, respectively).
Avoiding polypharmacy in psychiatric inpatients and adjusting drug regimens to safe equivalent doses could reduce ADEs during hospitalization.
在精神病学中,联合用药或高精神药物剂量会增加药物不良事件(ADE)的发生率。然而,联合用药与 ADE 之间的全部关系尚不清楚,并且很少有研究评估过精神药物的等效剂量与 ADE 之间的关系。因此,我们进行了一项回顾性分析,以阐明联合用药以及氯丙嗪(CP)、地西泮(DAP)和丙咪嗪等效剂量对住院患者所有 ADE 的影响。
我们纳入了 2016 年 4 月 1 日至 2018 年 3 月 31 日期间在日本一家医院住院的精神科患者。评估了 ADE 的严重程度和因果关系。进行了多项逻辑回归分析,以评估 ADE 的危险因素。
在分析的 462 例患者中,在纳入的 471 例患者中,有 145 例(31.4%)发生了 ADE。因果关系评估确定了 96.5%的“可能”。最常见的 ADE 是神经系统疾病(35%)。多项逻辑回归分析表明,随着用药数量的增加(≥5;p=0.026)、CP 等效剂量(p=0.048)和内分泌、营养和代谢紊乱(p=0.045),ADE 的发生率增加。DAP 等效剂量;传染病和寄生虫病;以及损伤、中毒和其他外部原因的后果降低了 ADE 的发生率(p=0.047、0.022 和 0.021)。
避免精神科住院患者的联合用药,并将药物方案调整为安全的等效剂量,可能会减少住院期间的 ADE。